We are representing a rare acquisition opportunity in the field of antibiotic and antimicrobial testing—a world-class, FDA-registered laboratory with a 35+ year track record of excellence in antimicrobial analytics.

This lab has built a strong reputation through its work with leading institutions, including the U.S. Pharmacopeia (USP), for potency assessments of several of its antibiotics used as global standards, as well as those of the European Pharmacopeia (EP) and the World Health Organization (WHO). The Lab has also served major companies such as DuPont, Johnson & Johnson, Calvin Klein, L’Oreal, and Church & Dwight, providing analytical studies across antibiotics and antimicrobial products.

Core services include:
=====================

-Antibiotic Potency Testing. (21-CFR/USP81)
– Cylinder plate and Tubidimetric formats
-Antimicrobial Evaluation (Medical/Industrial/Household Products)
-Microbial Limits Testing (CTFA/USP )
-Comparative potency assays
-Antibiotics Release testing (oral, topical, injectable, and ophthalmic dosage forms)

What sets this lab apart is its portfolio of proprietary and highly innovative technologies, developed by a scientist who has collaborated with the USP and the FDA on advancing antimicrobial testing standards.

Key proprietary technologies include:
=================================
-4–hour cylinder plate/diffusion assay for antibiotics (USP 81 compliant) — significantly faster than the 18–24 hour industry norm
-Novel microbial immobilization methods on solid surfaces for enhanced assay performance
-High-sensitivity antimicrobial activity screens (300x) for Gram-positive, Gram-negative, yeasts, and anaerobes
-Microbial limits test with rapid neutralization (CFTA/USP format)
-Fourth-generation automatic Zone Reader IP (optional): The lab founder pioneered the first semi-automated Zone Reader, which evolved into the industry-standard Omicon. Plans and know-how exist for a next-gen version in a $2B+ market.

Revenue & Asking Price:
================

While the lab has historically generated $500K–$800K annually with minimal marketing, last year’s revenue dipped to $314K due to the founder’s shift away from business development. It still remained slightly above break-even. However, a buyer with pharma contacts and better marketing can turn this into a lab with multi-million dollar revenue, as one needs just a handful of good clients developing or manufacturing antibiotic/antimicrobial products to make it a thriving business.

This lab is ideal for:

-A strategic buyer looking to enhance their antimicrobial testing capabilities with proprietary, field-tested methods
-A developer of new antimicrobials seeking to bring testing in-house
-A buyer with commercial expertise who sees the potential to scale a technically superior lab with high-margin services

Asking price:
===============
$700,000 for the lab and proprietary testing methods
Optional: $800,000 for the fourth-generation Zone Reader IP + revenue-sharing arrangement
If this opportunity aligns with your interests, we’d be happy to share more details, including a Confidential Information Memorandum.